Posttranslational intracellular silencing antibody platform

The present invention refers to a general method to select recombinant antibody domain (nanobodies) able to selectively bind and silencing intracellular post-translationally modified (PTM) targets. The antibodies obtained with the method described above can also be used for the validation of new therapeutic targets and for the generation of new diagnostic applications.